SERIES D COMMON STOCK PURCHASE WARRANT INHIBIKASE THERAPEUTICS, INC.Inhibikase Therapeutics, Inc. • May 20th, 2024 • Biological products, (no disgnostic substances) • New York
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Stockholder Approval Date (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on the 5-year anniversary of the Initial Exercise Date (the “Termination Date”) but not thereafter, to subscribe for and purchase from Inhibikase Therapeutics, Inc., a Delaware corporation (the “Company”), up to [ ] shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • May 20th, 2024 • Inhibikase Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of May 20, 2024, between Inhibikase Therapeutics, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
AMENDMENT TO COMMON STOCK PURCHASE WARRANTSCommon Stock Purchase Warrants • May 20th, 2024 • Inhibikase Therapeutics, Inc. • Biological products, (no disgnostic substances)
This AMENDMENT TO COMMON STOCK PURCHASE WARRANTS (this “Amendment”) is entered into as of May 22, 2024, by and between Inhibikase Therapeutics Inc., a Delaware corporation (the “Company”), and Armistice Capital Master Fund, Ltd. (the “Holder”).
PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • May 20th, 2024 • Inhibikase Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
